Browse studies

Find your next paid study

9 recruiting studies matching your filters

PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/II Platform Trial

PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed…

HER2-positive Breast CancerMetastatic CancerMetastatic Breast Cancer+29 more

Estimated

~$10 – $7,500

QuantumLeap Healthcare CollaborativeNCT05868226

Unified Network for Integrated Fluid Collection at Yale

UNIFY is a Yale-wide liquid biopsy master repository that prospectively collects Streck-tube blood, dried blood spots (and optional archival tissue) from Yale …

Molecular Residual DiseaseCancer

Estimated

~$10 – $750

Yale UniversityNCT07689864

Phase 2

A Pilot Clinical Trial of Motixafortide for Measurable Residual Disease (MRD) Sensitization in Acute Myeloid Leukemia (AML)

This is a pilot phase I study evaluating the effect of motixafortide on determination of measurable residual disease (MRD) level in patients with acute myeloid…

Acute Myeloid LeukemiaMeasurable Residual Disease

Estimated

~$10 – $6,250

Washington University School of MedicineNCT07392970

Phase 1

Phase I Study of Adoptive Immunotherapy With CD8+ and CD4+ Memory T Cells Transduced to Express an HA-1-Specific T Cell Receptor (TCR) for Children and Adults With Recurrent Acute Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation (HCT)

This phase I trial studies the side effects and best dose of CD4+ and CD8+ HA-1 T cell receptor (TCR) (HA-1 T TCR) T cells in treating patients with acute leuk…

Juvenile Myelomonocytic LeukemiaRecurrent Acute Biphenotypic LeukemiaRecurrent Acute Undifferentiated Leukemia+26 more

Phase 1

Novel Targeting of the Microenvironment to Decrease Metastatic Recurrence of High-Risk TNBC: A Randomized Phase II Study of Tetrathiomolybdate (TM) Plus Capecitabine in Patients With Breast Cancer at High Risk of Recurrence

There are two parts to this study. It is a phase 1b followed by a randomized phase 2 study to assess whether adding 3 years of adjuvant tetrathiomolybdate (TM)…

Triple Negative Breast CancerResidual Disease

Estimated

~$10 – $6,250

Dartmouth-Hitchcock Medical CenterNCT06134375

Phase 2

Phase II, Open-Label, Prospective Study of T Cell Receptor Alpha/Beta Depletion (A/B TCD) Peripheral Blood Stem Cell (PBSC) Transplantation for Children and Adults With Hematological Malignancies

This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (TCR α/β TCD) peripheral blood stem cell (PBSC) transplantation for c…

Hematologic MalignancyAcute LeukemiaRemission+21 more

Estimated

~$10 – $6,250

Masonic Cancer Center, University of Minnesota

The Caris Biorepository Research Protocol

The Biorepository for Caris Life Sciences is designed for the purpose of making quality biospecimens and associated clinical data available for research studie…

CancerEarly Detection of CancerMinimal Residual Disease

Estimated

~$10 – $1,050

Caris Science, Inc.NCT01499394

Phase 2

PREDICT-RD: Postoperative Molecular Residual Disease by ctDNA Surveillance in TNBC With Residual Disease

This is a Phase II, interventional, prospective, single-arm, multi-center study that will enroll patients with stage II/III triple negative breast cancer (TNBC…

Breast CancerResidual DiseaseTriple Negative Breast Cancer (TNBC)+1 more

Estimated

~$10 – $6,250

UNC Lineberger Comprehensive Cancer CenterNCT07069595

Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I)

A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided te…

TNBC - Triple-Negative Breast CancerMinimal Residual Disease

Estimated

~$10 – $1,050

Personalis Inc.NCT06230185